RecruitingPhase 4NCT07022496

Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals

Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial


Sponsor

Ain Shams University

Enrollment

120 participants

Start Date

Apr 26, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Caffeine extracted from green tea to abort acute attack of Migraine


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria1

  • Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.

Exclusion Criteria1

  • Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCaffeine (200 mg)

caffeine tablets

DRUGtriptans

Sumatriptan

DRUGNSAID (Nonsteroidal anti-inflammatory drugs)

Aspirin 250 mg, 81 mg, 75 mg

DRUGParacetamol (acetaminophen)

Paracetamol 250 mg


Locations(1)

Ainshams university

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07022496


Related Trials